Market Overview

UPDATE: Jefferies Raises PT on Pfizer on Attractive Valuation

Related PFE
UPDATE: BMO Capital Downgrades Pfizer
Benzinga's Top Downgrades
Week Ahead: July Jobs Report, FOMC and GDP (Fox Business)

In a report published Wednesday, Jefferies analyst Jeffrey Holford reiterated a Buy rating on Pfizer (NYSE: PFE), and raised the price target from $31.00 to $33.00.

In the report, Holford noted, “We remain positive on Pharmaceuticals and see valuation as attractive for most stocks. Our Top Pick in the US is AbbVie, with Novartis being our most preferred name in Europe. Sanofi, Roche and Pfizer remain high conviction Buy ratings. We point to Eli Lilly and GlaxoSmithKline as least preferred names.”

Pfizer closed on Tuesday at $29.11.

Posted-In: JefferiesAnalyst Color Price Target Analyst Ratings

 

Most Popular

Related Articles (PFE)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters